Revenue
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson (JNJ)
Price$276.44Cached quote
Net income
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $79.99B | $78.74B | $82.58B | $82.06B | $81.58B | $76.45B | $71.89B | $70.07B | $74.33B | $71.31B | $67.22B | $65.03B | $61.59B | $61.90B | $63.75B | $61.09B |
| Gross profit | $63.94B | $61.35B | $58.61B | $55.39B | $55.34B | $54.16B | $54.50B | $54.49B | $51.01B | $50.10B | $48.54B | $51.59B | $48.97B | $45.57B | $44.67B | $42.80B | $43.45B | $45.24B | $43.34B |
| Gross margin | 67.88% | 69.07% | 68.82% | 69.25% | 70.28% | 65.58% | 66.42% | 66.79% | 66.72% | 69.69% | 69.27% | 69.40% | 68.67% | 67.78% | 68.69% | 69.49% | 70.20% | 70.96% | 70.95% |
| Research & development | $14.66B | $17.23B | $15.09B | $14.13B | $14.28B | $12.16B | $11.36B | $10.78B | $10.59B | $9.14B | $9.05B | $8.49B | $8.18B | $7.67B | $7.55B | $6.84B | $6.99B | $7.58B | $7.68B |
| Operating expenses | $38.34B | $40.10B | $36.60B | $34.38B | — | — | — | — | — | — | — | $30.00B | $32.56B | $30.61B | $30.91B | $25.09B | $26.87B | — | — |
| Operating income | $25.60B | $21.25B | $22.01B | $21.01B | — | — | — | — | — | — | — | $21.59B | $16.41B | $14.96B | $13.77B | $17.70B | $16.58B | — | — |
| Operating margin | 27.17% | 23.92% | 25.84% | 26.27% | — | — | — | — | — | — | — | 29.05% | 23.01% | 22.25% | 21.17% | 28.74% | 26.79% | — | — |
| EBITDA | $41.05B | $24.78B | $23.32B | $26.61B | — | — | — | — | — | — | — | $25.48B | $20.52B | $18.62B | $16.92B | $20.64B | $19.36B | — | — |
| EBITDA margin | 43.59% | 27.90% | 27.38% | 33.26% | — | — | — | — | — | — | — | 34.29% | 28.77% | 27.70% | 26.02% | 33.51% | 31.27% | — | — |
| Net income | $26.80B | $14.07B | $35.15B | $17.94B | $20.88B | $14.71B | $15.12B | $15.30B | $1.30B | $16.54B | $15.41B | $16.32B | $13.83B | $10.85B | $9.67B | $13.33B | $12.27B | $12.95B | $10.58B |
| Net profit margin | 28.46% | 15.84% | 41.28% | 22.43% | 26.52% | 17.82% | 18.42% | 18.75% | 1.70% | 23.01% | 21.99% | 21.96% | 19.40% | 16.14% | 14.87% | 21.65% | 19.82% | 20.31% | 17.31% |
| Basic EPSper basic share | $11.13 | $5.84 | $13.88 | $6.83 | $7.93 | $5.59 | $5.72 | $5.70 | $0.48 | $6.04 | $5.56 | $5.80 | $4.92 | $3.94 | $3.54 | $4.85 | $4.45 | $4.62 | $3.67 |
| Diluted EPSper diluted share | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 | $5.51 | $5.63 | $5.61 | $0.47 | $5.93 | $5.48 | $5.70 | $4.81 | $3.86 | $3.49 | $4.78 | $4.40 | $4.57 | $3.63 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 11, 2026Form 4 | Wengel Kathryn EEVP, Chief TO and Risk Officer | SellCommon Stock | 10.0K | $241.15 | $2.41M | 114.3K |
| Feb 27, 2026Form 4 | Decker Robert JVP Corporate Controller | SellCommon Stock | 4.1K | $247.87 | $1.01M | 23.7K |
| Feb 20, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 1.3K | $245.66 | $324.8K | 25.4K |
| Feb 18, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 9.0K | $244.53 | $2.20M | 26.8K |
| Feb 18, 2026Form 4 | Schmid TimothyEVP, WW Chair, MedTech | SellCommon Stock | 13.6K | $244.20 | $3.33M | 26.8K |
Community posts
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...